The pCODR Expert Review Committee (pERC) has recommended the funding of ipilimumab (Yervoy) for the treatment of adults with advanced (unresectable or metastatic) melanoma, conditional on cost-effectiveness being improved to an acceptable level.

This is an initial recommendation; a final recommendation will be issued in due course.

For more details, go to: http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr-yervoy1stsub-in-rec.pdf